NantHealth Inc (NH) Stock Rating Upgraded by BidaskClub

NantHealth Inc (NYSE:NH) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other equities research analysts also recently commented on NH. Jefferies Group LLC decreased their target price on shares of NantHealth from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating and set a $6.00 target price (down from $8.00) on shares of NantHealth in a research report on Monday, August 21st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $8.55.

NantHealth (NYSE:NH) opened at 4.63 on Friday. NantHealth has a 1-year low of $4.00 and a 1-year high of $14.62. The firm’s market capitalization is $564.61 million. The stock’s 50 day moving average is $4.46 and its 200-day moving average is $5.81.

NantHealth (NYSE:NH) last posted its earnings results on Thursday, August 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.32). The business had revenue of $26.23 million for the quarter, compared to the consensus estimate of $31.28 million. NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. The company’s revenue was down 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) earnings per share. Analysts forecast that NantHealth will post ($0.70) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “NantHealth Inc (NH) Stock Rating Upgraded by BidaskClub” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/17/nanthealth-inc-nh-stock-rating-upgraded-by-bidaskclub.html.

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in NantHealth by 20.2% in the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock worth $1,792,000 after purchasing an additional 71,087 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in NantHealth in the 1st quarter worth about $998,000. Goldman Sachs Group Inc. grew its position in NantHealth by 91.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after purchasing an additional 81,024 shares in the last quarter. Northern Trust Corp grew its position in NantHealth by 133.9% in the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after purchasing an additional 86,955 shares in the last quarter. Finally, State Street Corp grew its position in NantHealth by 88.1% in the 2nd quarter. State Street Corp now owns 147,234 shares of the company’s stock worth $623,000 after purchasing an additional 68,963 shares in the last quarter.

NantHealth Company Profile

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply